

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Feb 2026

Efficacy and safety of Ethanol inhalation on early stage of COVID-19 (a clinical trial study)

Protocol summary

Study aim

Evaluation of the effectiveness of inhaled ethanol therapy in the control of Covid-19 disease

Design

Phase 3 clinical trial with a control group, parallel and single-blind type, in which the patient remains unaware of the name of the intervention drug. Random sampling on 86 patients.

Settings and conduct

This study was performed at Issa Bin Maryam Hospital in, Iran on patients who are temporarily hospitalized to receive remedicivir and dexamethasone or are hospitalized for several days in other wards. For patients in the ethanol group the oxygen flow meter or the nebulizer is poured with ethanol 35% .

Participants/Inclusion and exclusion criteria

Eligibility criteria Positive RT-PCR test Less than seven days from onset of symptoms Age 15-69 years; Non-Eligibility criteria Pregnancy History of asthma Alcoholism Epilepsy Contraindications to ethanol Disagreement of the treating physician

Intervention groups

In both groups, standard treatments are given according to the usual procedure. In the intervention group the inhaled ethanol is also added. Inhalation of 10 ml of 70% ethanol with 10 ml of distilled water in an oxygen flow meter with a flow of 2-3 liters per minute, every six hours for 15 minutes for up to five days will be our intervention. If the patient does not accept this method, the same amount of ethanol and distilled water is poured into the cold nebulizer and it is prescribed. In the control group, only 20 ml distilled water is poured into an oxygen flow meter instead of ethanol.

Main outcome variables

Symptoms, SPO2, WBC, CRP

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210725051981N1**

Registration date: **2021-10-19, 1400/07/27**

Registration timing: **prospective**

Last update: **2021-10-19, 1400/07/27**

Update count: **0**

Registration date

2021-10-19, 1400/07/27

Registrant information

Name

Ali Amoushahi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3667 6152

Email address

aliamoushahi@mail.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-10-26, 1400/08/04

Expected recruitment end date

2021-11-25, 1400/09/04

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Efficacy and safety of Ethanol inhalation on early stage of COVID-19 (a clinical trial study)

Public title

Inhalation Ethanol therapy in COVID-19

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Positive RT-PCR test of SARS-COV2 Less than 7 days of starting of signs or symptoms of COVID-19 Age 15-69 yr

Exclusion criteria:

Pregnancy History of Asthma History of Alcohol dependency History of Seizure Contraindication of Ethanol administration Disagreement of patient physician

Age

From **15 years** old to **69 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Data analyser

Sample size

Target sample size: **86**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization method: Simple randomization
Randomization tool: Random number table Even and zero digits are assigned to the ethanol treatment group and odd numbers to the control group.

Blinding (investigator's opinion)

Triple blinded

Blinding description

The blinding of the participant is done by not telling him the name of the drug under study. Analysts and staff collecting the data are given questionnaires in two groups named A and B.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committees of School of Medicine - Isfahan University of Medical Sciences

Street address

Isfahan University of Medical Sciences, Isfahan, Iran

City

Isfahan

Province

Isfahan

Postal code

81746-73461

Approval date

2021-09-25, 1400/07/03

Ethics committee reference number

IR.MUI.MED.REC.1400.506

Health conditions studied**1****Description of health condition studied**

COVID-19

ICD-10 code

U07.1

ICD-10 code description

COVID-19, virus identified

Primary outcomes**1****Description**

Requires non-temporary hospitalization

Timepoint

Daily until 5 days

Method of measurement

Counting the days

2**Description**

Needing to ICU admission

Timepoint

Days 7, 14, 21

Method of measurement

Evaluate medical file records

3**Description**

Mortality Rate

Timepoint

Days 7, 14, 21, 28

Method of measurement

Evaluate medical file records

4**Description**

Respiratory status of patients

Timepoint

Days from 1 to 5

Method of measurement

SPO2

5**Description**

Inflammatory condition
Timepoint
Days 1-5-14
Method of measurement
WBC counting -CRP titration

6

Description

Clinical status

Timepoint

Days 1-5-14

Method of measurement

Score from the table of clinical signs

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: In this group, in addition to the current treatment of Covid-19, which is remdesivir and methylprednisolone or dexamethasone, nebulizing ethanol is also added in this way. Four times a day, each time 10 ml of ethanol 70% of Sepahan bio-product CO. is poured in oxygen flowmeter or in the tank of the nebulizer device. After that, we add 10 ml of distilled water to it and encourage the patient to inhale it from mouth and nose. This technique must repeat for five days.

Category

Treatment - Drugs

2

Description

Control group: In this group, the current treatment of Covid-19, which is remdesivir and methylprednisolone or dexamethasone, is continued, and 20 ml of distilled water as placebo is poured into an oxygen flow meter or nebulizer, and the patient is encouraged to inhale it.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Isa Ben Maryam Hospital

Full name of responsible person

Ali Amoushahi

Street address

Shams Abadi St.

City

Isfahan

Province

Isfahan

Postal code

8134735945

Phone

+98 31 3235 1541

Email

aliamoushah@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Shaghayegh Haghju Javanmard

Street address

Hezar Jarib Ave.

City

Isfahan

Province

Isfahan

Postal code

81746-73461

Phone

+98 31 3668 0048

Fax

+98 31 3668 7898

Email

research@mui.ac.ir

Web page address

<https://research.mui.ac.ir/>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Elham Moazam

Position

Social medicine specialist

Latest degree

Specialist
Other areas of specialty/work
Public Health/Community Medicine
Street address
Shams Abadi
City
Isfahan
Province
Isfahan
Postal code
8134735945
Phone
+98 31 3235 1541
Fax
+98 21 8978 4962
Email
el_moazam@yahoo.com

Specialist physician
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Pasargad Complex, Ayneh Khane Avn.
City
Isfahan
Province
Isfahan
Postal code
8164644370
Phone
+98 31 3667 6152
Email
aliamoushah@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Ali Amoushahi
Position
Specialist Physician
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Ayneh Khane Avn.
City
Isfahan
Province
Isfahan
Postal code
8164644370
Phone
+98 31 3667 6152
Email
aliamoushah@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Ali Amoushahi
Position

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data is shareable.

When the data will become available and for how long

Access period starts 6 months after the results are published.

To whom data/document is available

It will be available only to researchers working in academic and scientific institutions.

Under which criteria data/document could be used

It is permissible to use this data to find patients who respond better to this treatment.

From where data/document is obtainable

Contact Ali Amoushahi by phone (00989131158298) or email (aliamoushah@gmail.com).

What processes are involved for a request to access data/document

The request will be answered in a week in consultation with other partners in the project.

Comments